Sunday, March 29, 2015

Could This Study Help Lead to a Cure for Select Multiple Sclerosis Patients?





























For a disease that affects 2.5 million people around the globe and more than 400,000 people in the United States, it's a shame that so little is known about multiple sclerosis despite the amount of money being put into research of the disease.

Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate: STUDY

























Sunday, March 1, 2015

Alkermes' multiple sclerosis prodrug looks good in Phase I, has Biogen Idec's Tecfidera in its sights































Dr. Elliot Ehrich

Alkermes ($ALKS) said the safety profile of its clinical-stage multiple sclerosis drug compares favorably to that of Biogen Idec's Tecfidera, citing the candidate's Phase I trial results on 104 patients.

Forward Pharma: One of Baupost’s new positions






























Baupost adds new stake in Forward Pharma
Seth Klarman’s The Baupost Group added a 11.72% stake in Forward Pharma (FWP). A 13G filing  in November indicated that the fund owns 5,367,300 shares in Forward Pharma.

Alkermes Announces Positive Topline Results From Phase 1 Study of ALKS 8700 for Treatment of Multiple Sclerosis


























–– Novel, Oral Product Candidate Provided Monomethyl Fumarate Exposures Comparable to TECFIDERA®, With Favorable Gastrointestinal Tolerability ––